These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19300899)

  • 21. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
    Sadikot SM; Mogensen CE
    Diabetes Res Clin Pract; 2008 Dec; 82(3):391-5. PubMed ID: 18945509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Are the guidelines correct? Should all patients with coronary heart disease or diabetes be treated with a statin?].
    Pöss J; Böhm M; Laufs U
    Med Klin (Munich); 2009 Jan; 104(1):74-8. PubMed ID: 19142597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Metformin should not be used by patients with reduced renal function].
    Gudmundsdottir H; Brørs O; Os I
    Tidsskr Nor Laegeforen; 2008 Apr; 128(8):936-7. PubMed ID: 18431417
    [No Abstract]   [Full Text] [Related]  

  • 24. Diabetic dyslipidemia and the heart.
    Vasudevan AR; Garber AJ
    Heart Fail Clin; 2006 Jan; 2(1):37-52. PubMed ID: 17386875
    [No Abstract]   [Full Text] [Related]  

  • 25. [Life expectancy decreased by 1/3rd. Who to sink the vascular risk of type 2 diabetic patients?].
    MMW Fortschr Med; 2001 Dec; 143(49-50):56. PubMed ID: 11808457
    [No Abstract]   [Full Text] [Related]  

  • 26. Metformin in heart failure.
    Inzucchi SE; Masoudi FA; McGuire DK
    Diabetes Care; 2007 Dec; 30(12):e129. PubMed ID: 18042738
    [No Abstract]   [Full Text] [Related]  

  • 27. Metformin and risk of cardiovascular disease.
    Turner RC; Holman RR
    Cardiology; 1999; 91(3):203-4. PubMed ID: 10516415
    [No Abstract]   [Full Text] [Related]  

  • 28. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin therapy in patients with type 2 diabetes complicated by heart failure.
    Inzucchi SE; Masoudi FA; McGuire DK
    Am Heart J; 2007 Dec; 154(6):e45. PubMed ID: 18035066
    [No Abstract]   [Full Text] [Related]  

  • 30. ACE inhibitors reduce heart-related death in type 2 diabetics.
    Health News; 2004 Oct; 10(10):15. PubMed ID: 15584126
    [No Abstract]   [Full Text] [Related]  

  • 31. DREAM and ADOPT: rosiglitazone does what it says on the packet.
    Bilous R
    Diabet Med; 2007 Feb; 24(2):107-9. PubMed ID: 17257270
    [No Abstract]   [Full Text] [Related]  

  • 32. [Diabetes mellitus in coronary bypass surgery: risks and chances. Treatment concepts for a particularly challenging group of patients].
    Lauruschkat AH; Ennker J
    Herz; 2008 Apr; 33(3):212-21. PubMed ID: 18568316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
    Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
    [No Abstract]   [Full Text] [Related]  

  • 34. Interplay of diabetes and coronary heart disease on cardiovascular mortality.
    Boccara F; Cohen A
    Heart; 2004 Dec; 90(12):1371-3. PubMed ID: 15547003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes mellitus in patients with myocardial infarction complicated by heart failure: a 'low ejection fraction' equivalent?
    Gore MO; Masoudi FA; McGuire DK
    Eur J Heart Fail; 2010 Nov; 12(11):1156-8. PubMed ID: 20965878
    [No Abstract]   [Full Text] [Related]  

  • 36. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The fate of diabetic patients--epidemiological study. III. Prevalence of coronary heart disease in diabetics depending on the method of hypoglycaemic treatment. Warsaw.
    Królewski A; Czyźyk A; Kopczynski J; Janeczko D; Puncewicz B
    Acta Med Pol; 1978; 19(3):363-71. PubMed ID: 735877
    [No Abstract]   [Full Text] [Related]  

  • 38. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
    Mancini T; Mazziotti G; Doga M; Carpinteri R; Simetovic N; Vescovi PP; Giustina A
    Bone; 2009 Oct; 45(4):784-8. PubMed ID: 19527806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapies for type 2 diabetes and coronary artery disease.
    DeVries JH
    N Engl J Med; 2009 Oct; 361(14):1408-9; author reply 1409-10. PubMed ID: 19802918
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased risk of type 2 diabetes from a family history of coronary heart disease and type 2 diabetes.
    Yeung EH; Pankow JS; Astor BC; Powe NR; Saudek CD; Kao WH
    Diabetes Care; 2007 Jan; 30(1):154-6. PubMed ID: 17192352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.